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Abstract
Background Overall, HER2-amplified female breast cancer
(FBC) is associated with a high grade, an aggressive phenotype
and a poor prognosis. In male breast cancer (MBC) amplifica-
tion of HER2, located on chromosome 17, occurs at a lower
frequency than in FBC, where it is part of complex rearrange-
ments. So far, only few studies have addressed the occurrence
of chromosome 17 alterations in small MBC cohorts.
Methods Multiplex ligation-dependent probe amplification
(MLPA) and fluorescence in situ hybridization (FISH) were
used to detect and characterize copy number changes on chro-
mosome 17 in a cohort of 139 MBC. The results obtained
were compared to those in FBC, and were correlated with
clinicopathological features and patient outcome data.
Results We observed a lower frequency of chromosome 17
copy number changes with less complex rearrangement pat-
terns in MBC compared to FBC. Chromosome 17 changes in
MBC included gains of 17q and losses of 17p. Whole
chromosome 17 polyploidies were not encountered. Two re-
current chromosome 17 amplicons were detected: on 17q12
(encompassing the NEUROD2, HER2, GRB7 and IKZF3
gens) and on 17q23.1 (encompassing the MIR21 and
RPS6KB1 genes). Whole arm copy number gains of 17q were
associated with decreased 5 year survival rates (p=0.010).
Amplification of HER2 was associated with a high tumor
grade, but did not predict patient survival. Although copy
number gains of HER2 and NEUROD2 were associated with
a high tumor grade, a highmitotic count and a decreased 5 year
survival rate (p=0.015), only tumor size and NEUROD2 copy
number gains emerged as independent prognostic factors.
Conclusions In MBC chromosome 17 shows less complex
rearrangements and fewer copy number changes compared
to FBC. Frequent gains of 17q, encompassing two distinct
amplicons, and losses of 17p were observed, but no whole
chromosome 17 polyploidies. Only NEUROD2 gains seem
to have an independent prognostic impact. These results sug-
gest different roles of chromosome 17 aberrations in male
versus female breast carcinogenesis.
Keywords Male breast cancer . Oncogenes . Copy number
changes .Multiplex ligation-dependent probe amplification
1 Introduction
Previous studies using multiplex ligation-dependent probe
amplification (MLPA) and comparative genomic hybridiza-
tion (CGH) in male breast cancer (MBC) revealed clear dif-
ferences in gene copy number changes compared to female
breast cancer (FBC), pointing towards differences in carcino-
genesis between MBC and FBC [1, 2]. Copy number changes
on chromosome 17q have been extensively studied in differ-
ent cancer types including FBC. This is primarily due to the
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presence of the ERBB2 oncogene (HER2) on chromosome
17q. Amplification of HER2 is found in about 10–20 % of
FBC and usually leads to over-expression of its encoded pro-
tein. HER2 amplification/over-expression also correlates with
a high grade, a high mitotic index, a worse prognosis and a
favorable response to targeted therapy with trastuzumab
[3–8]. Next to HER2, several other oncogenes are located on
chromosome 17, such as TOP2A and PPM1D [9–11]. To as-
sess the HER2 amplification status by in situ hybridization,
correction for polysomy of chromosome 17 is widely applied,
although several studies have shown that such polysomy is
very rare in FBC, and that the copy number status of the
centromere does not reliably represent the number of chromo-
some 17 copies. Instead, it has been found that chromosome
17 may show very complex rearrangements in FBC [12–15].
It has also been found that inMBCHER2 amplification occurs
at a lower frequency than in FBC (2–8 % versus 10–20 %,
respectively) [1, 6, 14, 16–18]. So far, only a few (mainly
CGH) studies have been published dealing with chromosome
17 alterations in relatively small MBC cohorts [2, 19], and
their association with disease outcome has not previously
been reported.
In the present study we aimed to characterize copy number
changes on chromosome 17 in a large MBC cohort using a
dedicated chromosome 17 MLPA kit that has previously been
used to study chromosome 17 polysomy in FBC [14]. In ad-
dition, we performedHER2 chromogenic in situ hybridization
(CISH) and correlated the results with several clinicopatho-
logic features and patient outcome data.
2 Materials and methods
2.1 Patient material and characteristics
Consecutive surgical invasive male breast cancer (MBC)
specimens were collected from 1986 to 2011 at four different
pathology labs in the Netherlands (i.e., St. Antonius Hospital
Nieuwegein, Diakonessenhuis Utrecht, University Medical
Center Utrecht, Laboratory for Pathology East Netherlands)
as reported in more detail before [1, 20, 21], and at three
pathology labs in Germany (i.e., in Paderborn, Cologne, Kas-
sel). Hematoxylin and eosin (HE) stained slides were
reviewed by four experienced observers (PJvD, RK, AM,
ML) to confirm the diagnosis and to type and grade the tumors
according to current WHO standards. Pathology reports were
used to retrieve information on age, tumor size and lymph
node status. A total of 139 cases, from which the paraffin
blocks contained enough tumor cells for DNA isolation, were
included in the present study. The clinicopathological features
of these cases are listed in Table 1. The average age of the
MBC patients was 67 years. The tumor sizes ranged from 0.2
to 7.2 cm. In 114 cases the lymph node status was assessed
through axillary lymph node dissection or sentinel node pro-
cedures, and in 56 % of these patients lymph node metastases
were noted. The majority of the MBC cases was diagnosed
(WHO criteria) as invasive ductal carcinoma. According to
the modified Bloom and Richardson score [22] most tumors
were classified as grade 2 or grade 3. Mitotic activities were
assessed as reported before [23], with a mean mitotic index of
12 per 2 mm2. In all cases, the estrogen receptor (ER) and
progesterone receptor (PR) expression and HER2 amplifica-
tion status were re-assessed as described before [20]. Tissue
microarray (TMA) slides were used for immunohistochemical
detection of ER and PR expression. Chromogenic in situ hy-
bridization (SPoT-Light HER2 CISH kit, Invitrogen) was
used for HER2 copy number assessment. The HER2 gene
was considered to be amplified when more than 50 % of the
tumor cells showed 5–10 single dots or small clusters of dots
per nucleus (i.e., low level amplification), or more than 10
single dots or large clusters of dots per nucleus (i.e., high level
amplification).
2.2 Intrinsic subtype classification
Immunohistochemical staining was used to classify the tu-
mors into five intrinsic subtypes: luminal type A (ER+ and/
or PR+, HER2- and Ki-67 low), luminal type B (ER+ and/or
PR+, and HER2+ and/or Ki67 high), HER2 driven (HER2+
and ER-/PR-), basal-like (ER-/PR-/HER2-, and CK5/6+ and/
or CK14+ and/or EGFR+) and unclassifiable triple negative
(negative for all six markers), as described before [20].
2.3 DNA extraction and MLPA analysis
Representative tumor areas were identified in HE stained
slides and dissected with a scalpel from 8 μm thick paraffin
sections as reported before [24]. DNAwas extracted by over-
night incubation of the samples in proteinase K (10 mg/ml;
Roche, Almere, The Netherlands) at 56 °C, boiling for 10 min
and subsequent clearance by centrifugation. Five μl of the
resulting DNA solution was used for MLPA analysis. MLPA
was performed according the manufacturers’ instructions
(MRC Holland, Amsterdam, The Netherlands), using a Veriti
96-well thermal cycler (Applied Biosystems, Foster City, CA,
USA). A recently designed kit (P004-C1; MRC Holland),
containing five probes for five 17p genes and twenty-six
probes for seventeen 17q genes, was used. The kit contained
twelve additional reference probes. All tests were performed
in duplicate. Negative reference samples (normal breast and
blood cells) as well as a positive control sample (tumor sample
with high level HER2 amplification as determined by CISH)
were included in each MLPA run as reported before [1]. The
PCR products were separated by electrophoresis on an ABI
3730 capillary sequencer (Applied Biosystems) and the final
gene copy number ratios were calculated using Genescan v4.1
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(Applied Biosystems) and Coffalyser v9.4 (MRC-Holland)
software packages. For genes represented by more than one
probe in the kit, the mean of the copy number ratios in dupli-
cate was calculated. Cut-off values were set as reported before,
with>1.3 to 2.0 for gain, > 2.0 for amplification and<0.7 for
loss. Gene copy number increase (or total gain) was defined by
values>1.3, including gain and amplification. Values between
0.7 and 1.3 were considered normal [6, 25]. Whole chromo-
some arm loss or gain was defined by copy number loss of
more than 75 % of all the probes, as reported before using
array-CGH [26]. Partial gain on the long arm of chromosome
17 was defined as any probe showing copy number increase.
The MBC chromosome 17 copy number data were also com-
pared to chromosome 17 copy number data of 111 FBC cases
reported before, but based on a different MLPA design [14].
2.4 Statistical analyses
Statistical calculations were performed using IBM SPSS
for Windows version 20.0. Associations between gene
copy numbers and clinicopathological features were calcu-
lated using the Pearson Chi-square test (or Fisher’s exact
test when appropriate) for categorical variables. Grade, tu-
mor size and mitotic count were dichotomized as usual [1,
21]. Unsupervised hierarchical clustering using the statis-
tical program R (www.r-project.org) was performed to
identify relevant clusters. We used the maximum distance
and Ward’s clustering method, and calculated the stability
of the clusters with pvclust, as reported before [1].
Information regarding prognosis and therapy was
retrieved from the Integral Cancer registration of the
Netherlands (IKNL). Survival data were available from
100 cases with a mean follow-up of 5.6 years. Therefore,
we based the survival analyses on 5 year survival rates. For
univariate survival estimates, Kaplan-Meier plots were an-
alyzed using the log rank test. Multivariate survival analy-
ses were performed using Cox regression, including the
variables that were found to be significant in univariate
analyses. Corrections for multiple comparisons were ap-
plied according to Holm-Bonferroni.
Table 1 Baseline
clinicopathological features of
139 male breast cancers
Characteristics All cases (n=139) Characteristics All cases (n=139)
Age, years Lymph node metastasis n=114
Mean 67 (range 32–89) Absent 50 (44 %)
≤50 13 (9 %) Present 64 (56 %)
>50 126 (91 %)
Immunohistochemistry
Histological type ER
Ductal 124 (90 %) (+) 128 (92 %)
Lobular 3 (2 %) (−) 11 (8 %)
Invasive cribriform 3 (2 %) PR
Mixed (ductal/lobular) 3 (2 %) (+) 93 (67 %)
Mucinous 2 (1 %) (−) 46 (33 %)
Papillary 2 (1 %) AR
Invasive micropapillary 1 (1 %) (+) 112 (81 %)
Adenoid cystic 1 (1 %) (−) 27 (19 %)
HER2 (CISH)
Tumor size (mean), cm 2.3 (n=135) (+) 5 (4 %)
T1 70 (50 %) (−) 134 (96 %)
T2 61 (45 %)
T3 4 (3 %) Intrinsic subtypes
Luminal A 108 (74 %)
Mitotic activity index/2 mm2 Luminal B 27 (19 %)
<8 mitoses 54 (39 %) Her2 driven 0 (0 %)
8–14 mitoses 34 (24 %) Basal like / 10 (7 %)
15 or > mitoses 51 (37 %) unclassified triple negative
Histological grade
I 33 (24 %)
II 60 (43 %)
III 46 (33 %)
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3 Results
3.1 Identification of chromosome 17 copy number changes
in male breast cancers
Multiplex ligation-dependent probe amplification (MLPA)
was used to assess the copy number status of chromosome
17 in a cohort of 139 male breast cancers (MBC). The results
obtained and its comparison to female breast cancer (FBC)
cases are presented in Fig. 1 and supplementary Table A.
Overall, we found a lower frequency of copy number changes
with less complex patterns in MBC compared to those in
FBC. In 51/139 (36.7 %) cases no copy number alterations
were seen in MBC in any of the genes included in the MLPA
assay. Copy number increases were found to be most frequent
on 17q, present in 78/139 (56 %) of the cases, and copy num-
ber losses were found to be most frequent on 17p (36/139;
26 %). Six of the 139 MBC cases (4 %) showed a whole 17q
arm gain. None of the MBC cases showed a whole chromo-
some 17 gain.NEUROD2, IKZF3,HER2 andMIR21were the
most commonly amplified genes, and copy number gains
were most common for theMIR21 and RPS6KB1 genes. Copy
number losses were most frequently observed for the MNT,
TP53 and PMP genes, all three located on 17p (Fig. 2).
3.2 Chromosome 17 copy number alterations
and associations with clinicopathological features
In 8/139 (5.8 %) of the MBC cases the HER2 status was
assessed by MLPA. In four of these eight cases MLPA ampli-
fication ratios between 2.0 and 2.5 were observed, whereas the
other four showed amplification ratios above 2.5. The cases
that exhibited amplification rates between 2.0 and 2.5 by
MLPA showed no amplification by CISH, whereas four of
the cases with HER2 amplification as detected by CISH
showed amplification by MLPA with ratios>2.5. One case
that was interpreted as showing a low level amplification by
CISH also showed a gain, but no high-level amplification, by
MLPA (Table 2).
Three of the eight cases (37.5 %) showing HER2 amplifi-
cation by MLPA also exhibited a whole arm gain of 17q,



























































































Fig. 1 Copy number changes detectecd by MLPA of 11 genes on chromosome 17 in 139 male breast cancers compared to 111 female breast cancers
(female data derived from [14])
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Two of these cases also showed a partial gain of the short arm,
combined with copy number loss of other loci on the short
arm. Amplification of the 17q12 region, including the
NEUROD2, GRB7 and IKZF3 genes, was observed in 6/8
(75 %) of the cases withHER2 amplification, and two of these
cases showed an additional amplification of the RARA/TOP2A
gene region on 17q21.2. The NEUROD2, HER2, GRB7 and
IKZF3 genes were also frequently found to be gained, whereas
copy number loss of this region was observed in none of the
cases. Another region of frequent copy number gain was
found on 17q23.1, were the MIR21 and RPS6KB1 genes are
located (Fig. 2). Taken together, we identified two recurrent
amplicons: one on 17q12 (encompassing the NEUROD2,
HER2, GRB7 and IKZF3 genes) and one on 17q23.1
(encompassing the MIR21 and RPS6KB1 genes).
As can be deduced from Table 3, copy number increases of
several genes on 17q were correlated with unfavorable clini-
copathological features, such as a high mitotic count and a
high grade (NEUROD2, HER2, GRB7, IKZF3, RPS6KB1,
PPM1D, AXIN2 and UNC13D), a high grade and a large size
(SGCA), or a high grade alone (BRCA1 and MIR21). Ampli-
fication of NEUROD2 was found to be correlated with a high
mitotic count and a high grade. Amplification of the HER2
andGRB7 genes was found to be correlated with a high grade,
and amplification of the IKZF3 genewith a highmitotic count.
After correction for multiple comparisons, the correlation be-
tween copy number gains of the NEUROD2 gene and a high
mitotic count and a high grade remained significant (Table 3).
3.3 Cluster analysis reveals association with luminal
breast cancer sub-type
After unsupervised hierarchical cluster analysis, we found
that the NEUROD2, HER2, GRB7 and IKZF3 genes clus-
tered together (p<0.001) (Supplementary Fig. A). Consid-















































































total gain (>1.3) amplification (>2.0) loss (<0.7)
Fig. 2 Copy number changes detected by MLPA in 22 genes on chromosome 17 in 139 male breast cancers
Table 2 Her2/Neu status based on immunohistochemistry and CISH in correlation with Her2/Neu amplification status based on MLPA






Positive (3+) high amplification positive 3.795
Positive (3+) low amplification positive 4.859
Positive (3+) high amplification positive 4.292
Positive (3+) high amplification positive 2.536
Negative (2+) low amplification positive 1.448*
Negative (0) no amplification negative 2.100
Negative (0) no amplification negative 2.003
Negative (1+) no amplification negative 2.023
Negative (2+) no amplification negative 2.269
(*only gain by MLPA, no amplification)
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encompassing 12 cases characterized by chromosome 17
whole arm copy number gains and amplifications of the
NEUROD2, HER2, GRB7 and IKZF3 genes with signifi-
cantly more luminal type B cases than luminal type A cases
(p=0.010). The distribution of other clinicopathological
features (age, grade, mitotic index, size and lymph node
status) was not found to be significantly different in this
cluster compared to the other remaining cases.
3.4 Tumor size and NEUROD2 copy number gain act
as independent prognostic factors
Survival data were available from 100 cases with a mean
follow up of 5.6 years. Grade 3 (p=0.026), high mitotic
count (>8 mitoses/2 mm2; p=0.028), large tumor size
(>2.0 cm; p=0.031), luminal type B (p=0.042), positive
HER2 status by CISH (low and high level amplification;
p=0.039), NEUROD2 copy number gain (p=0.015),
HER2 copy number gain (p=0.015) and whole chromo-
some 17q arm gain (p=0.010) were found to be associated
with a decreased 5 year survival rate. The above (3.3)
described clusters showed no correlation to survival. After
multivariate Cox regression only tumor size and
NEUROD2 gene copy number gain remained as indepen-
dent prognostic factors (Fig. 3).
4 Discussion
The aim of the present study was to detect and characterize
copy number changes on chromosome 17 in a large cohort of
male breast cancers (MBC) using MLPA. The majority of
cases showed chromosome 17 aberrations, mainly copy num-
ber gains on 17q (78/139; 56 %) and copy number losses on
17p (36/139; 26 %). Only six of the 139 cases (4 %) showed a
whole 17q arm gain. None of the cases showed whole chro-
mosome 17 gains, which is in line with previous female breast
cancer (FBC) studies [13–15]. Compared to FBC [12], how-
ever, we found a lower frequency of chromosome 17 copy
number changes with less complex patterns of genomic rear-
rangements in MBC.
Previously, chromosome CGH was used to assess copy
number gains and losses in MBC [2, 19]. Rudlowski et al.
[19] reported gains on 17q in 36% of the MBC tested. In their
study 17q gain was not associated with any of the clinicopath-
ological features studied. In the present study we found that
58 % of the MBC showed gains on 17q and 14 % showed
high-level amplifications on 17q. In line with our study,
Tommasi et al. [2] found that both losses and gains on chro-
mosome 17 were less prominent in MBC than in FBC.
Whole arm gains of 17q and concomitant gains of the
WSB1 gene located near the centromere were frequently seen
in association with amplification of the HER2 gene (37.5 %).
Table 3 Correlations between
gene copy number changes and
clinicopathological features in
139 male breast cancers
Gene Location Mitotic index Size Grade Lymph node status




NEUROD2 17q12 <0.0001 <0.0001
ERBB2 17q12 0.046 0.017
GRB7 17q12 0.016 0.006
IKZF3 17q12 0.001 0.028
RARA 17q21.2 0.01
BRCA1 17q21.31 0.01 0.021
SGCA 17q21.33 0.025 0.021
MIR21 17q23.1 0.019
RPS6KB1 17q23.1 0.002 0.001
PPM1D 17q23.2 0.047 0.033
AXIN2 17q24.1 0.008 <0.0001
UNC13D 17q25.1 <0.0001 <0.0001
Correlation between gene amplification (>2.0) and clinicopathological features




Blank: non-significant results. Bold: after correction for multiple comparisons
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The 17p arm, however, only showed partial copy number
gains and losses, or no alterations at all in these cases, arguing
against the occurrence of whole chromosome 17 polysomies
in MBC, as has previously been observed in FBC [12]. These
findings suggest that FISH correction for polysomy with cen-
tromere probes may result in a misleading HER2 gene status
assessment, as described before in FBC [12].
Although in itself rare, the co-amplification and co-
clustering of genes on the HER2 neighboring segment con-
taining NEUROD2, GRB7 and IKZF3 in 75 % of the MBC
cases points towards the existence of a large amplicon on 17q,
which is different from what has previously been seen in FBC
[12, 27, 28]. This latter amplicon includes both the HER2 and
NEUROD2 genes, and is in line with a similar prognostic
value of both NEUROD2 and HER2 copy number gains in
the present study.
We found that theHER2 gene exhibited copy number gains
in 21% of theMBC cases, but a true amplification (byMLPA)
was only seen in 5.8 % of the cases, which is in line with
previous HER2 expression studies [16, 18], but lower than
that reported by Tommasi et al. [2], who found HER2 to be
amplified in 30 % of MBC cases by CGH. This discrepancy
may be explained by the different technique and smaller sam-
ple size used in the latter study. We found that HER2 was
amplified at a lower frequency in MBC compared to previous
MLPA studies in FBC (5.8 % versus 20 %) [6]. In concor-
dance with our previous studies in FBC and MBC, HER2
amplification detected by MLPA correlated strongly with
HER2 amplification detected by CISH [1, 14].
We found that a positive HER2 status, defined by both
CISH (p=0.039) and MLPA (p=0.015), was correlated with
a decreased 5 year survival rate. HER2 amplification was rel-
atively rare (5.8 %) and, by itself, not found to serve as a
predictor of survival in univariate survival analyses. This
notion may be due to the relatively small number of cases
showing HER2 amplification. Copy number gain of
NEUROD2 was also found to be correlated with a decreased
5 year survival (p=0.015), as was whole 17q arm gain (p=
0.010). In multivariate Cox regression analyses, NEUROD2
copy number gains exhibited an independent prognostic value
next to tumor size. NEUROD2 itself, coding for a protein that
plays a role in neuronal differentiation and neuronal cell fate,
is unlikely to be involved in breast cancer prognosis. There-
fore, other neighbouring genes are more likely to act as drivers
of this amplicon. Some candidate genes such as MED1,
MED24 andDARPP-32 are located near theNEUROD2 gene.
MED1 encodes a subunit of the master transcriptional co-
regulator Mediator/TRAP co-activator complex [29] and is a
key ERα co-activator [30, 31]. The MED1/MED24 complex
was previously found to be frequently and simultaneously
over-expressed in FBC and to play an important role in the
growth of breast cancer cells via the RAS-mitogen-activated
protein kinase (MAPK) pathway [32]. Several studies have
indicated that the MED1 gene may be located within the
HER2 amplicon [27, 28] and that it may play a key role in
HER2-mediated tamoxifen resistance [33]. The neighboring
DARPP-32 gene codes for a Dopamine and cAMP-regulated
phosphoprotein, and its over-expression has been implicated
in resistance to tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) receptor targeted therapy in cancer
[34]. It would be interesting to further assess their copy num-
ber status and prognostic value in MBC.
The second amplicon encompasses RPS6KB1, a protein
coding gene reported to be amplified and over-expressed in
10-30 % of FBC. We observed RPS6KB1 copy number gains
in 30 % of the MBC cases. Its encoded protein, a ribosomal
protein S6 kinase, is positioned downstream of the PI3K and
mTOR pathways and is involved in protein synthesis, cellular
Fig. 3 Survival plots of 100 male breast cancers stratified for NEUROD2 copy number status (right) and tumor size (left)
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growth and proliferation, which makes it an interesting target
for therapy. Further research is, however, needed to clarify the
exact role of RPS6KB1 copy number changes in MBC.
The TOP2A gene encodes topoisomerase 2 alpha, a nuclear
protein which plays an important role in DNA replication and
mitosis. It is the main target of adjuvant anthracycline-based
chemotherapy. TOP2A has previously been reported to be fre-
quently amplified in FBC. The prognostic value of TOP2A gene
amplification in FBC is as yet, however, controversial [9]. We
found a lower percentage of TOP2A copy number gain in MBC
compared to FBC (15 % versus 27 %) [14]. Gain or amplifica-
tion of TOP2A does not seem to be of prognostic value forMBC.
The PPM1D gene, previously reported to be frequently
amplified in FBC (25 %), was found to be amplified in a
low percentage (2.9 %) of MBC, and to be gained in 16.5 %
of MBC in our current study. Gain of PPM1D showed a trend
towards a correlation with high grade and high mitotic count,
but did not appear to be a predictor of survival, as has been
reported before in FBC [11].
In conclusion, we found that MBC is characterized by copy
number gains on 17q, with two distinct amplicons, and copy
number losses on 17p. Like in FBC, no whole chromosome
17 polysomy was found. MBC shows a similar, but less com-
plex pattern of chromosome 17 rearrangements and fewer
copy number changes than FBC. These results suggest a dif-
ferent role of chromosome 17 in male and female breast can-
cer development. Whole arm copy number gain of 17q was
associated with HER2 copy number gain. HER2 and
NEUROD2 copy number gains were found to be associated
with a high tumor grade, a high mitotic count and a decreased
5 year survival rate. NEUROD2 copy number gain seems to
serve as an independent prognostic factor, but is unlikely to be
a driver of the associated amplicon. Further research is needed
to assess copy number changes in neighboring genes, includ-
ing their putative prognostic/therapeutic role in MBC.
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